Brazil’s health jurisdiction, Anvisa, said late on Monday it wouldn’t advise importing Sputnik V, the Covid-19 vaccine manufactured by Russia. The Gamaleya Research Institute, a part of Russia’s Ministry of Health, developed the vaccine, also referred to as Gam-Covid-Vac. A peer-reviewed research published in The Lancet in February said the vaccine had an efficiency rate of 91.6 per cent . Brazil’s health regulator resisted the vaccine on Monday, citing security concerns.
Brazil’s requirement for vaccines is urgent: it’s been battered by a few of the planet’s worst outbreaks, driven by the highly infectious P.1 virus version . However, Anvisa explained that significant security evaluations hadn’t been completed Sputnik V, which questions remained regarding the vaccine’s advancement, security and production.
Data concerning the vaccine’s effectiveness were “unsure,” Gustavo Mendes Lima Santos, Anvisa’s director of medication and biological products, said in a lengthy demonstration describing the health authority’s conclusion. The demonstration said there were “key questions” which had gone unanswered, such as concerns about possible adverse events, such as clotting.